Table 1.

Breast cancer cohorts explored in this study: anthracycline-based neoadjuvant chemotherapy (BRCA-ACT) for HER2-negative patients and targeted therapy for HER2+ breast cancers (BRCA-TCHP).

	BRCA-ACT	BRCA-TCHP
N	242	129
Pathologic response
Responder	66	66
Non-responder	176	63
Recurrence-free Survival
Event observed, N [median time-to-event, months]	48 [25.0]	N/A
Censored, N [median time-to-last-followup, months]	109 [53.3]	N/A
Unavailable	85	129
HER2 status
Positive, N	0	129
Negative, N	242	0
Hormone Receptor status
Positive, N	152	86
Negative, N	90	43
Age, years	49.6 ± 10.5	50.1 ± 11.1
Longest diameter, mm	5.4 ± 2.9	4.4 ± 2.9
Cohort
Training	98	69
Testing	144	60